Central and peripheral airway/alveolar sites of exhaled nitric oxide in acute asthma

Arthur F Gelb,1 Steven C George,2 Philip E Silkoff,3 Anita Krishnan,4 Christine Fraser,4 Colleen Flynn Taylor,4 Chris M Shinar,5 Tamara Maginot4

ABSTRACT

Introduction Central airway nitric oxide flux (J’awNO) and peripheral airway/alveolar nitric oxide concentration (CANO) during asthma exacerbation has not been investigated after correction for axial NO back-diffusion.

Methods After measuring exhaled NO (fraction of exhaled nitric oxide (FEN; ppb) at 50, 100, 150 and 200 ml/s, J’awNO (n/l/s) and CANO (ppb) were calculated using the two-compartment model and corrected for axial NO back-diffusion. Fifteen (8 males), non-smoking, patients with moderate-to-severe treated (inhaled corticosteroid (ICS) and inhaled long-acting β2-agonist (LABA)) asthma, age 57 ± 13 years (mean ± SD), were studied at baseline, during exacerbation prior to oral corticosteroid, and during recovery after an 8 day tapering prednisone course. Based on earlier asthma studies without correction, it was hypothesised that with correction for NO axial back-diffusion, the incidence of abnormal J’awNO and CANO at baseline and after exacerbation would be ≥30% in 15 patients with asthma with 80% power.

Results At baseline when clinically stable, after 180 μg of albuterol, forced expiratory volume in 1 s (FEV1; litres) was 78 ± 26% predicted (p=0.009) with increased F2NO at 50 ml/s (p=0.01) and J’awNO (p=0.02), but CANO was normal compared with the controls. During exacerbation FEV1 (litres) was 57 ± 20% predicted (p=0.02), with increased F2NO at 50 ml/s (p=0.01) and J’awNO (p=0.004), but CANO was normal. Recovery results were similar to baseline. Two of 15 patients with asthma always had normal exhaled NO gas exchange.

Conclusions The central airways were the major site of abnormal NO flux in 13 of 15 patients with moderate—severe asthma when stable and during exacerbation and could be easily detected with abnormal F2NO at 50 ml/s. CANO was normal.

Clinical trial number NCT00576069.

Measurement of the fraction of exhaled nitric oxide (F2NO; ppb) is a relatively simple, reproducible and non-invasive test for monitoring airway inflammation.1 Increased F2NO in asthma is accepted as a surrogate for predominantly eosinophilic-mediated inflammation in central airways and increased response to inhaled corticosteroid (ICS).1–5 The currently accepted method of measuring F2NO at a single constant expiratory flow rate, usually 50 ml/s, is incapable of separating out whether the source of increased NO production is the large central airways or the peripheral small airway/alveolar site, or both.6 However, increased F2NO predominantly reflects large central airways. Therefore, several investigators have developed newer techniques to discriminate NO gas exchange between large central airways and peripheral small airways/alveolar compartments.7–12

Using a two-compartment model developed by Tsoukias and George,11 central airway NO flux and peripheral airway/alveolar concentration can be estimated by measuring F2NO at multiple expiratory flows and plotting NO output versus expiratory flow. The slope of the linear regression line between NO output versus flow reflects the peripheral airway/alveolar NO concentration (CANO; ppb), whereas the y-intercept reflects central airway NO flux J’awNO (n/l/s).11 We13 14 and others2 15 16–21 using this model11 have previously reported NO gas exchange in central as well as peripheral airway/alveolar sites in those with mild1 13 14 16–17 and moderate—severe2 15 16–21 clinically stable asthma. However, two groups independently2 22 have also demonstrated, both experimentally and theoretically, axial back-diffusion of NO from proximal to peripheral airway/alveoli, against the direction of exhalation. Furthermore, this may contaminate peripheral airway/alveolar levels, leading to an underestimation of central airway NO flux and an overestimation of peripheral airway/alveolar NO levels. Axial NO back-diffusion has not been previously accounted for in those with asthma with abnormal expiratory airflow limitation.

The current prospective outpatient study evaluated F2NO using the two-compartment model before and after correcting for NO axial back-diffusion12 22 in clinically stable, non-smoking, treated patients with asthma with moderate—severe expiratory airflow limitation who were not previously studied. Our goal was to evaluate and partition central airway versus peripheral airway/alveolar sites of NO concentration at baseline, during an ensuing spontaneous asthma exacerbation prior to initiation of oral corticosteroid, and following recovery with oral corticosteroid. This has not been investigated previously. Based on our earlier asthma studies13 14 without correction for axial NO back-diffusion, we hypothesised the incidence of abnormal J’awNO and CANO at baseline and after exacerbation to be ≥30% in 15 patients with asthma with 80% power after correction for axial NO back-diffusion.

METHODS

Patient selection

We recruited adult patients with moderate—severe persistent asthma who were on maintenance combination inhaled corticosteroid (ICS)/inhaled long-acting β2-agonist (LABA), fluticasone propionate 250 μg/salmeterol 50 μg twice a day (F250/
Asthma

SSO) (Advair250/50, GlaxoSmithKline, Research Triangle Park, North Carolina, USA) for at least 1 year. Smoking history was <5 pack-years and currently all were non-smokers for at least 5 years. All asthma patients were clinically stable for at least 8 weeks and were monitored in our tertiary referral outpatient clinic for ≥3 years. Their asthma symptoms and spirometry were optimal when compared with clinical and spirometric results obtained over the previous ≥3 years. When needed for acute relief, medical treatment included a short-acting inhaled β2 agonist (albuterol sulphate metered dose inhaler (MDI) or solution) and inhaled antimuscarinic agent ipratropium bromide (Atrovent MDI or solution, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA). All those with asthma were off oral corticosteroids, antibiotics and leukotriene-modifying agents for at least 8 weeks before entry into the study. Serum eosinophils and immunoglobulin E (IgE) were measured only at baseline. All subjects with asthma had demonstrated bronchodilator reversibility within the past 2 years defined as an increase in forced expiratory volume in 1 s (FEV1) 200 ml and ≥12%, 15 min after 150 μg of albuterol via MDI. Our goal was to study prospectively exhaled NO gas exchange in the initial 15 patients with moderate–severe asthma who developed an acute exacerbation requiring oral corticosteroids.

Normal controls
Normal values for FENO were obtained from 40 normal subjects (20 males), age 57 ± 9 years (mean ± SD), who were asymptomatic, healthy lifelong non-smokers with no history of lung disease and not on any medications. No provocative bronchoconstrictor challenge tests were done on normal subjects. All subjects with asthma and normal subjects studied had given informed consent for participation. This study was approved by both Lakewood Regional Medical Center IRB and Western IRB, Olympia, WA, and registered as NCT00576069.

Measurement of exhaled NO gas exchange
All subjects abstained from food and coffee for 2 h and alcohol for 12 h prior to studies. Exhaled NO was measured in triplicate prior to spirometry at four separate constant expiratory flow rates: 50, 100, 150 and 200 ml/s, and the mean of three values obtained within 10% of each other was reported using a Sievers NOA 280 chemiluminescence analyser with varying expiratory airflow resistors (GE Analytical Instruments, Boulder, Colorado, USA) as previously described. Furthermore, to avoid nasal NO contamination, a mouth piece of >5 cm H2O was used, as previously recommended. The NO analyser was calibrated daily with a known concentration (45 ppm) and before each study. In our previous studies, we noted that measurement of baseline NO (awNO) is essential and was used in eight of the subjects with asthma. The decision to initiate oral corticosteroids was determined by the emergency ward or other physician who was initially unaware of the study until the patient with asthma informed the physician, and the Principal Investigator was immediately notified. Asthma exacerbation was treated with an 8 day tapering course of oral prednisone starting with 40 mg. Concurrent use of antibiotics was optional and was used in eight of the subjects with asthma. No laboratory study was initiated to definitively determine the aetiology of superimposed acute bronchitis. Measurement of F2NO was not used to guide clinical treatment.

Statistical methods
In our previous studies, we noted that >60% of patients with clinically stable moderate–severe asthma had significantly increased peripheral lung CANO without correction for NO axial back-diffusion and, after re-examination, >50% after

Lung function studies
When clinically stable at baseline, and during recovery following treatment with oral corticosteroid, subjects with asthma were instructed to continue all their medications, except to withhold MDI albuterol sulphate and/or ipratropium bromide for 6 h, and the LABA DPI (dry powder inhaler) for 24 h prior to testing. Obviously, during asthma exacerbation, medications were not withheld. Our techniques for measuring spirometry, thoracic gas volumes and airway resistance using plethysmography, and diffusing capacity have been previously published.

Protocol: therapeutic intervention with oral corticosteroid
Once selected for this prospective, single-blind, open label to patient study, patients with asthma were continued on maintenance combination ICS plus inhaled LABA. Concurrent acute relief medications when needed included aerosolised and/or nebulised albuterol sulphate and ipratropium bromide. Definition of asthma exacerbation requiring oral corticosteroids included increasing complaints of cough±sputum, chest tightness, wheezing and shortness of breath for ≥1 day. These symptoms were not relieved despite at least three treatments with aerosolised and/or nebulised 2.5 mg albuterol sulphate and 0.5 mg ipratropium bromide within 8 h and there was a concomitant decrease in FEV1 ≥0.5 litres from baseline. In addition, absence of fever and no acute change on a chest x-ray were required. The decision to initiate oral corticosteroids was determined by the emergency ward or other physician who was initially unaware of the study until the patient with asthma informed the physician, and the Principal Investigator was immediately notified. Asthma exacerbation was treated with an 8 day tapering course of oral prednisone starting with 40 mg. Concurrent use of antibiotics was optional and was used in eight of the subjects with asthma. No laboratory study was initiated to definitively determine the aetiology of superimposed acute bronchitis. Measurement of F2NO was not used to guide clinical treatment.

Thorax first published as 10.1136/thx.2009.132696 on 13 July 2010. Downloaded from http://thorax.bmj.com/ on October 6, 2023 by guest. Protected by copyright.
correction. In the current study, we needed to evaluate a minimum of 15 patients with moderate–severe asthma at baseline and during exacerbation to achieve 80% power to detect a ≥30% incidence of increased peripheral C_{ANO} after correction for NO axial back-diffusion. Forty normal age-matched subjects were compared with patients with asthma at baseline using two-group unpaired t tests. Data for those with asthma were initially analysed to determine normality distribution using Shapiro–Wilk test. Because of non-parametric data, analysis of variance (ANOVA) using ranks with repeated measurement was used, with clinical status including stable baseline, exacerbation and recovery as the within factor. Paired t test was used to compare change in clinical status within the same group. S+ version for Windows was used for analysis (Tibco Software, Palo Alto, California, USA). Values for p < 0.05 were considered significant.

**RESULTS**

**Baseline studies**

We prospectively studied 15 (8 males) patients with moderate–severe asthma, age 57 ± 13 years (mean ± SD) who had been treated with inhaled combination ICS + LABA for 3.6 ± 0.4 years. Results of lung function studies in normal subjects and those with asthma before and 15 min after 180 μg of albuterol by MDI are presented in table 1. Those with asthma had baseline vital capacity of 3.0 ± 1.0 litres (87 ± 29% predicted), total lung capacity 5.8 ± 0.9 litres (108 ± 19% predicted), residual volume 2.8 ± 1.0 litres (145 ± 47% predicted), functional residual capacity 3.5 ± 0.9 litres (133 ± 62% predicted), single breath diffusing capacity 23 ± 6 ml/min/mm Hg (98 ± 27% predicted) and diffusing capacity/alveolar volume 5.0 ± 0.8 ml/min/mm Hg/l (126 ± 20% predicted). Compared with 40 age-matched normals, values for forced vital capacity (FVC), FEV₁ and FEV₁/FVC were significantly decreased at baseline. High-resolution, thin-section lung CT emphysema scores were 9 (mean ± SD), indicating none or trivial emphysema, and no bronchiectasis was noted in the 15 subjects with asthma. At baseline, serum IgE was 215 ± 154 mg/dl and total blood eosinophil count 0.42 ± 0.36 x 10⁶ cells/l in the 15 subjects with asthma.

**Baseline NO production**

Compared with age-matched normal subjects, when clinically stable, baseline values for F₂NO at 50 ml/s, ppb (p = 0.01), F₂NO at 100 ml/s, ppb (p = 0.005), Γ^awNO nl/s (p = 0.02) and C_{ANO} ppb (p = 0.04) in the subjects with asthma were significantly increased prior to Condorelli correction. The value for central airway NO flux Γ^awNO after correction for axial back-diffusion of NO remained significantly increased (p = 0.02). However, after correcting for NO axial back-diffusion, values for C_{ANO} were zero or slightly negative (not statistically different from zero) both in normal subjects and all those with asthma (p = 0.2), indicating no or trivial peripheral airway/alveolar C_{ANO} concentration. Two of the 15 subjects with asthma at baseline had normal values for NO gas exchange despite abnormal spirometry (see table 1 and figures 1–5).

**Spirometry and NO production during asthma exacerbation prior to initiation of oral corticosteroid**

During asthma exacerbation which occurred on average 101 ± 10 days (mean ± SD) after baseline, there was a significant decrease in FVC and FEV₁ both before and after 180 μg of albuterol. During asthma exacerbation, compared with baseline, there was a significant increase in F₂NO production at 50 ml/s (p = 0.005), at 100 ml/s (p < 0.001) and in Γ^awNO (p = 0.004) both before and after correction (p = 0.004) for NO axial back-diffusion. There was increased C_{ANO} before (p = 0.001), but not after (p = 0.8) correction for NO axial back-diffusion in all those with asthma. These results allowed us to reject the hypothesis that ≥30% of those with asthma after correction for NO axial back-diffusion would have increased C_{ANO}. Two of the subjects with asthma who had normal NO gas exchange at baseline had similar normal values during exacerbation. These two subjects had similar spirometry and serum IgE and total eosinophil count to the other 13 subjects with asthma with abnormal NO gas exchange (see table 1 and figures 1–5).

**Spirometry and NO production in recovery after an 8 day oral corticosteroid course**

After 10 ± 2 days (mean ± SD) following initiation of an 8 day tapering course of oral prednisone, there was a significant increase in spirometry (p < 0.005), compared with values obtained during acute exacerbation. There was also a significant decrease in F₂NO production at 50 ml/s (p < 0.001), at 100 ml/s (p < 0.001), Γ^awNO and C_{ANO} compared with values obtained during exacerbation (p < 0.01). Results for Γ^awNO (p = 0.01) were

**Table 1** Lung function and nitric oxide (NO) gas exchange in normal subjects and patients with asthma at baseline, during exacerbation and following recovery

<table>
<thead>
<tr>
<th></th>
<th>Normal control</th>
<th>Stable baseline asthma F₂50/S50</th>
<th>Asthma exacerbation F₂50/S50</th>
<th>Asthma recovery F₂50/S50 plus oral corticosteroid</th>
</tr>
</thead>
<tbody>
<tr>
<td>FVC (litres) pre/post 180 μg of albuterol</td>
<td>3.6 ± 1.0</td>
<td>3.2 ± 0.9/3.3 ± 0.9, p = 0.2</td>
<td>2.5 ± 0.8/2.9 ± 0.9, p = 0.004/0.14</td>
<td>3.2 ± 0.8/3.2 ± 0.7, p = 0.005/0.19</td>
</tr>
<tr>
<td>FVC % predicted pre/post</td>
<td>97 ± 13</td>
<td>89 ± 20/94 ± 22, p = 0.2</td>
<td>66 ± 17/74 ± 17, p = 0.001/0.001</td>
<td>80 ± 17/88 ± 22, p = 0.001/0.006</td>
</tr>
<tr>
<td>FEV₁ (litres)</td>
<td>2.8 ± 0.7</td>
<td>2.1 ± 0.8/2.2 ± 0.8, p = 0.009</td>
<td>1.5 ± 0.7/1.8 ± 0.7, p = 0.001/0.001</td>
<td>2.1 ± 0.7/2.2 ± 0.6, p = 0.001/0.01</td>
</tr>
<tr>
<td>FEV₁ % predicted pre/post</td>
<td>93 ± 14</td>
<td>71 ± 23/78 ± 26, p = 0.004</td>
<td>49 ± 20/57 ± 20, p = 0.001/0.002</td>
<td>68 ± 21/77 ± 24, p = 0.001/0.002</td>
</tr>
<tr>
<td>FEV₁/FVC % pre/post</td>
<td>79 ± 5</td>
<td>66 ± 13/68 ± 14, p = 0.005</td>
<td>61 ± 13/64 ± 13, p = 0.06/0.04</td>
<td>70 ± 12/70 ± 12, p = 0.07/0.2</td>
</tr>
<tr>
<td>F₂NO at 50 ml/s (ppb)</td>
<td>22 ± 10</td>
<td>40 ± 23 ± 0.01</td>
<td>90 ± 47 ± 0.003</td>
<td>44 ± 19 ± 0.001</td>
</tr>
<tr>
<td>F₂NO at 100 ml/s (ppb)</td>
<td>14 ± 9</td>
<td>24 ± 11 ± 0.005</td>
<td>53 ± 27 ± 0.001</td>
<td>27 ± 9 ± 0.001</td>
</tr>
<tr>
<td>Large airway NO (nl/s)</td>
<td>1.0 ± 0.6</td>
<td>1.7 ± 1.1 ± 0.02</td>
<td>4.2 ± 2.8 ± 0.004</td>
<td>2.0 ± 1.0 ± 0.01</td>
</tr>
<tr>
<td>Large airway NO (nl/s) corrected</td>
<td>1.7 ± 1.0</td>
<td>3.0 ± 1.8 ± 0.02</td>
<td>7.2 ± 4.8 ± 0.004</td>
<td>3.4 ± 1.7 ± 0.01</td>
</tr>
<tr>
<td>Small airway/alveolar NO (ppb)</td>
<td>3.9 ± 2.4</td>
<td>5.6 ± 3.0 ± 0.04</td>
<td>11 ± 6 ± 0.001</td>
<td>5.9 ± 2.2 ± 0.01</td>
</tr>
<tr>
<td>Small airway/alveolar NO (ppb) corrected</td>
<td>1.9 ± 2.3</td>
<td>2.2 ± 2.7 ± 0.02</td>
<td>2.6 ± 4.3 ± 0.8</td>
<td>1.9 ± 2.4 ± 0.4</td>
</tr>
</tbody>
</table>

Lung function and NO results are mean ± SD. Measurements of NO gas exchange were obtained prior to spirometry. Spirometry obtained in patients with asthma are before and after 180 μg of albuterol by metered dose inhaler. Corrected indicates the NO gas exchange values in this table have been corrected for axial NO back-diffusion.12 F₂50/S50, fluticasone propionate 250 μg/salmeterol 50 μg; F₂NO, fraction expired nitric oxide; FEV₁, forced expiratory volume in 1 s; FVC, forced expiratory volume; ppb, parts per billion.
unchanged after correction for NO axial back-diffusion. However, CANO was significantly decreased before (p = 0.01) but not after (p = 0.4) correction for NO axial back-diffusion. The two subjects with asthma who had normal values for NO gas exchange at baseline and despite exacerbation also had normal values during recovery after oral corticosteroid. Their response to oral corticosteroid was similar to that of those with asthma with elevated NO gas exchange (see table 1 and figures 1–5).

**DISCUSSION**

Spirometry and exhaled NO at multiple expiratory flow rates were measured to determine the contribution of central and peripheral airway/alveolar NO production sites using the two-compartment model. Data were obtained initially at baseline, during asthma exacerbation prior to initiating oral corticosteroid, and subsequently during recovery immediately following an 8 day course of tapering oral corticosteroid. At baseline, despite optimal clinical stability, there was significantly abnormal spirometry and both increased central airway NO flux and peripheral airway/alveolar CANO before correction for NO axial back-diffusion. However, after correction, peripheral airway/alveolar CANO was normal compared with 40 age-matched healthy, non-smoking controls with normal lung function. During asthma exacerbation, with greater expiratory airflow limitation, central airway NO flux, \( J'_{awNO} \), was increased before and after correction for NO axial back-diffusion. The results suggest that central airways are the predominant site of increased NO gas exchange in 13 of 15 patients with asthma with moderate-severe expiratory airflow limitation studied at baseline and following exacerbation. Two of the 15 studied patients with asthma had normal values for NO gas exchange at baseline, during exacerbation and following recovery after oral corticosteroid. These two patients may have a non-eosinophilic-mediated inflammatory pathway. However, their clinical and physiological response to 8 day tapering oral corticosteroid treatment was similar to that of the

**Figure 1** Measurement of total exhaled nitric oxide (FENO) at 50 ml/s in age-matched normal subjects and patients with asthma on fluticasone 250 μg/salmeterol 50 μg when stable at baseline, during exacerbation and following recovery. ppb, parts per billion. Each figure notes the median, 1–3 interquartile with 5–95% bars in normal subjects and those with asthma, and asthma outliers are represented by a line.

**Figure 2** Measurement of large/central airway nitric oxide (NO) flux (nL/s) in age-matched normal subjects and patients with asthma on fluticasone 250 μg/salmeterol 50 μg when stable at baseline, during exacerbation and following recovery. NO values are uncorrected for axial back-diffusion.

**Figure 3** Measurement of large/central airway nitric oxide (NO) flux (nL/s) adjusted for axial NO back-diffusion in age-matched normal subjects and patients with asthma on fluticasone 250 μg/salmeterol 50 μg when stable at baseline, during exacerbation and following recovery.

**Figure 4** Measurement of small and peripheral airway/alveoli CANO (ppb) in age-matched normals subjects and patients with asthma on fluticasone 250 μg/salmeterol 50 μg when stable at baseline, during exacerbation and following recovery. Nitric oxide (NO) values are uncorrected for axial back-diffusion.
other 13 subjects with asthma, with increased central airway $J_{awNO}$ flux. Furthermore, measurement of $F_eNO$ at 50 ml/s, which reflects predominantly large airway NO flux, may be both more relevant and practical, especially when peripheral airway/alveolar NO is normal.

**Peripheral airway/alveolar NO production and inhaled corticosteroid**

It has been reported that increased central airway NO flux and peripheral lung $C_{ANO}$ in asthma reflects predominantly eosinophilic-mediated inflammatory pathways, presumably stimulated by upregulated or overexpressed inducible nitric oxide synthase (iNOS), or less probably constitutive nitric oxide synthase (cNOS). The present study contradicts in part our previous observations of increased peripheral lung $C_{ANO}$ in 60% of clinically stable patients with moderate–severe asthma that did not take into account axial NO back-diffusion. Upon re-examination of our original data and after correcting for axial NO back-diffusion, peripheral $C_{ANO}$ still remained increased in 30% of those with asthma. The discrepancy with the present results may in part be related to different cohorts of patients with asthma and the therapeutic regimen. Previous studies uncorrected for axial NO back-diffusion noted increased central airway NO flux and increased peripheral airway/alveolar $C_{ANO}$ in those with clinically stable asthma with mild and moderate–severe obstruction despite ICS. Review of published data from van Veen et al suggests normal peripheral $C_{ANO}$ production after we corrected for NO axial back-diffusion. Alternatively, previously published results, also without correction for axial NO back-diffusion, noted increased central NO flux but normal peripheral $C_{ANO}$ in clinically stable patients with asthma with mild and moderate–severe $D_LNO$ 10–14 exhalory airflow limitation despite ICS. Kerckx and Van Muylem noted normal peripheral airway/alveolar NO concentration in those with mild asthma after correction for NO axial back-diffusion. However, Brindicci et al reported increased $C_{ANO}$ during exacerbation in those with moderate–severe asthma. However, re-examination of their published data suggests normal $C_{ANO}$ after correction for NO back-diffusion. The reduction in $C_{ANO}$ following oral corticosteroid in the present study is similar to our previous experience and that of Berry et al in those with clinically stable asthma prior to correction for NO axial back-diffusion. We favour the new hypothesis that <30% of those with moderate–severe asthma at baseline and after exacerbation have increased $C_{ANO}$ with a 95% upper confidence limit for incidence of increased $C_{ANO}$ of 22%. We would have to study 15 additional subjects with asthma to achieve a 95% upper confidence limit for an incidence of increased $C_{ANO}$ <10% (p<0.001).

**Potential mechanism(s) for peripheral NO before and after correction for axial NO diffusion**

Previously, Silkoff et al reported that methacholine-induced bronchoconstriction in subjects with asthma, with reduction in epithelial surface area, decreased NO production by ~15%. The partial pressure of NO in the small airway and alveolar area ($P_{LNO}$) is equal to the production of NO by surrounding tissue ($V_{NO}$)/diffusing capacity of NO from air space into surrounding blood vessels ($D_{LNO}$). Therefore, either an increase in NO tissue production as an inflammatory response (increased iNOS and/or cNOS) or reduced $D_{LNO}$, or both could account for increased $P_{LNO}$. Lehtimaki et al have previously shown an inverse relationship between $C_{ANO}$ and pulmonary capillary diffusing capacity in alveolitis. In asthma, we have previously noted that the increase in $C_{ANO}$ was attributed to an increase in NO tissue production, probably related to increased iNOS, and suspect that this is also operant during asthma exacerbation since reduction in $D_{LNO}$ in asthma is unlikely. Furthermore, it would have a relevant effect on NO axial back-diffusion. The increase if any in peripheral lung $C_{ANO}$ in clinically stable patients with asthma is modestly downregulated by inhaled compared with systemic corticosteroids.

The original two-compartment model developed by Tsoukas and George to describe central and peripheral airway/alveolar site of NO concentration failed to account for axial back-diffusion of NO from the central airways towards the alveoli. This error may have led to underestimation of central airway NO flux and overestimation of peripheral/alveolar $C_{ANO}$. Subsequent contributions from Condorelli et al for NO axial back-diffusion estimated that large airway NO flux is 1.7-fold greater if the flow range is between 50 and 250 ml/s, with trivial NO levels in peripheral lung units in normal subjects (approaching zero). The negligible level of $C_{ANO}$ in normal subjects is probably due to the great affinity between periacinar NO and the haemoglobin molecule in the surrounding blood pool.

Important experimental observations by Kerckx and Van Muylem have also demonstrated the inhomogeneous distribution of NO production in healthy adults, with the majority of exhaled NO coming from very proximal airways and ‘larger’ peripheral airways of <17 generation, with little contribution from the lung periphery after correcting for axial NO back-diffusion. The response following histamine-induced bronchoconstriction in normal subjects has been studied by Verbanck et al who noted its potential effect to increase convective flow of NO and FeNO at 50 ml/s by a paradoxical decrease in axial back-diffusion of NO. Additionally, Kerckx et al reported the inhomogeneous airway contribution of NO production in those with stable asthma without expiratory airflow obstruction and noted a minimal peripheral contribution of NO production, similar to normal subjects, after correcting for axial NO back-diffusion. These observations are similar to those noted by Condorelli et al and reinforce the present observations in those with asthma with abnormal expiratory airflow limitation. It is possible that during an acute asthma exacerbation, the correction factor for axial NO back-diffusion would be smaller, due to
a smaller cross-sectional area available for back-diffusion of NO through constricted airways. This would result in a potential underestimation of $C_{ANO}$ and overestimation of $J_{awNO}$ using the current technique and interpretation. There are currently no experimental data available on back-diffusion of NO during acute asthma.

**Large airway NO flux and ICS, and potential mechanism(s)**

Central airway NO flux is the product of NO production in bronchial wall mucosa ($P_{CwNO}$) and bronchial NO diffusing capacity ($D_{awNO}$) which reflects transfer of NO from the airway wall to the lumen of expired air and is proportional to the lumen surface area and transfer coefficient. While we did not measure $C_{aw}$ and $D_{awNO}$, this could be estimated as noted by Silkoff et al. using low exhaled flow rates (5–10 ml/s) and application of a non-linear method. We suspect that in those with both clinically stable and unstable asthma moderate dose ICS (F250/S50) is probably unable significantly to suppress increased bronchocative iNOS and/or resident eNOS in the larger airways to reduce bronchial wall ($C_{aw}$) NO production effectively. Review of the individual data in the present study indicates that 2 of the 15 studied subjects with asthma had normal baseline values for large and small airway/alveolar $C_{ANO}$ and without subsequent increase during exacerbation. Despite lack of induced sputum and/or airway cellular analyses, this implies a non-eosinophilic inflammatory-mediated pathway. In summary, the present asthma cohort, and after correction for NO axial back-diffusion, the central airways remain the predominant site of increased NO gas exchange in the subjects with asthma studied at baseline, following exacerbation and subsequent recovery.

**Clinical implications**

Several investigators have addressed the clinical role of add-on monitoring of exhaled NO at a single expiratory airflow rate, usually at 50 ml/s, to help guide inhaled and/or systemic corticosteroid dosing in those with clinically stable and unstable asthma, in addition to guideline recommendations which include spirometry. Results of five double-blind randomised control trials comparing add-on F$_2$NO versus usual guidelines including spirometry were only equivocal. This suggests that routine serial measurements of F$_2$NO for clinical asthma management does not appear necessary. However, multiple issues related to study design question the validity of the conclusions. The present study is an extension of our original investigation to define and partition central and peripheral airway/alveolar sites of NO concentration in those with stable asthma at baseline and during exacerbation, initially without and now with correction for NO axial back-diffusion. This requires measuring NO gas exchange at four separate expiratory flow rates. However, the current results suggest predominantly central airway sites of abnormal NO gas exchange, presumably reflective of eosinophilic-mediated inflammation, in 13 of the 15 studied subjects with asthma. While measuring F$_2$NO at a single expiratory flow rate at 50 ml/s does not provide any information about the contribution of $C_{ANO}$ in peripheral sites, it appears that NO overproduction in asthma can be localised to the central airways. Furthermore, it should be emphasised that increased F$_2$NO at 50 ml/s, a surrogate of central airway increased NO flux, correlates only modestly with induced sputa eosinophilia and severity of asthma.

**REFERENCES**

Lung alert

Non-invasive ventilation (NIV) immediately after extubation reduces ventilatory failure and 90-day mortality in patients with hypercapnia

This randomised open controlled trial took place from 2005 to 2007 in three Spanish intensive care units. The aim was to assess whether non-invasive ventilation (NIV) would prevent respiratory failure and hence re-intubation, an independent risk factor for mortality, nosocomial pneumonia and length of hospital stay in patients who developed hypercapnia (arterial carbon dioxide tension >45 mm Hg) during a spontaneous breathing trial prior to extubation. The secondary end point was 90-day mortality.

One hundred and sixty-four consecutive patients were registered and 106 underwent randomisation. Fifty-four were assigned NIV (mean pressure 17/4 cm H₂O) immediately after extubation. The secondary end point was 90-day mortality.

Statistically significant differences in the development of respiratory failure were found in the NIV group compared with the controls (15% vs 45%), the impact occurring within the first 24 h. There was, however, no difference in the rate of re-intubation or in the length of stay in hospital or in the intensive care unit (ICU). This may have been a result of rescue NIV being deployed in both groups; 20/25 controls in respiratory failure met the criteria for rescue NIV, leading to 75% avoiding re-intubation, a better outcome than in previous reports.

Although overall mortality in the ICU and hospital did not differ, 90-day mortality was significantly reduced in the NIV group, suggesting longer term benefits of NIV which cannot be explained by re-intubation avoidance alone and warrants further assessment.


I Stone

The Royal London Hospital, London, UK

Correspondence to Dr I Stone, The Royal London Hospital, Whitechapel, London E1 1BB, UK; ian.stone@bartsandthelondon.nhs.uk